CD274 and non-small cell lung carcinoma: Patients with high tumor PD-L1 expression as defined by a proportional score of ≥50 % (PS ≥50 %) demonstrated improved objective response rates of 45 % compared with 19 % in all enrolled NSCLC patients [111].